True legacy preservation requires hardening your household against invisible, systemic risk. As a core feature of CourMed’s Resident Privilege onboarding protocol, we embed an advanced multi-cancer early detection (MCED) utility directly into your private health architecture via Cancerguard® by Exact Sciences.

Rather than relying on traditional, reactive medical models that wait for symptoms to surface, the Resident Privilege establishes a proactive, data-driven biological baseline the moment you join the community.

The Technology: Multi-Biomarker Detection

Traditional cancer screenings are fundamentally limited, covering only a few routine areas and leaving the vast majority of aggressive cancers undetected until late stages. Cancerguard® changes the paradigm by screening for more than 50 types and subtypes of cancer from a single, discreet blood draw.

How the Utility Operates:

• Cellular Surveillance: As cells cycle, they shed fragments of material into your bloodstream. Malignant cells release distinct, abnormal circulating tumor DNA (cfDNA) and protein markers.

• The Multi-Biomarker Assay: Cancerguard® utilizes a sophisticated laboratory-developed test that scans these blood-based signals simultaneously, looking for the earliest molecular indicators of active disease.

• Targeted Early Alerts: The test provides an “early alert” system for lethal, hard-to-detect diseases—such as pancreatic, liver, gastric, and ovarian cancers—which lack routine guideline screenings and are traditionally discovered too late.

Onboarding Tiers: Scaling to Your Legacy

To systematically manage risk across your family office or estate footprint, CourMed deploys the Cancerguard® molecular baseline through three structured onboarding tiers:

1. The Principal Tier (1 Test)

• The Target: The primary driver, founder, or principal leader of the estate.

• The Goal: A targeted baseline audit to clear the primary decision-maker of immediate, hidden biological volatility, protecting the core asset engine from operational downtime.

2. The Estate Tier (4 Tests)

• The Target: The nuclear leadership core of the household (Principal, Spouse, and Primary Trustees).

• The Goal: Securing the immediate domestic ecosystem. This matrix ensures that a sudden health event cannot disrupt the active governance or immediate continuity of the family estate.

3. The Legacy Tier (8 Tests)

• The Target: Multi-generational saturation, covering patriarchs, matriarchs, adult children, and key heirs.

• The Goal: Formulated for families navigating the complexities of generational wealth transfer. This comprehensive audit secures the succession line across generations.

Clinical Reality & Full Disclosure

Operating an institutional-grade Private Health Office requires total data transparency and clinical integrity. To maintain absolute clarity regarding the boundaries of molecular screening, all residents should review the following operational parameters:

• Not a Total Replacement: Cancerguard® is designed as a complementary early-warning mechanism. It does not replace gold-standard, routine routine clinical screenings such as mammograms or colonoscopies. A negative result does not permanently guarantee the absolute absence of all malignancies.

• Specific Indications: The test has a 97% clinical specificity (correctly identifying those without the disease) and a 64% overall sensitivity across all stages. It is not indicated for the detection of breast or prostate cancers, as these specific tumor types exhibit low DNA “shed rates” in early stages.

• Target Demographics: The test is optimized for asymptomatic individuals between the ages of 50 and 84 who have not received a cancer diagnosis within the past three years.

Navigating the Data: Managing False Positives

No diagnostic or screening tool is completely infallible, and multi-cancer early detection tests can yield false negative or false positive results. A False Positive occurs when the test flags a cancer signal, but subsequent clinical imaging shows no tumor is present.

The CourMed Infrastructure Advantage: In a standard healthcare model, a positive signal or a false positive creates severe administrative friction and immense family anxiety. Under the Resident Privilege framework, CourMed completely mitigates this fallout.

A positive result is not a final diagnosis—it simply means a signal was detected. If a signal is flagged, our private clinical team instantly steps in. We bypass traditional medical backlogs to immediately coordinate and facilitate the necessary diagnostic resolution—such as a specialized neck-to-pelvis contrast CT or PET scan—to pinpoint or safely rule out any abnormalities with absolute precision.

Secure Your Onboarding Baseline

Do not leave your family’s human capital exposed to biological blind spots. Integrate sovereign molecular security into your estate’s infrastructure today.

Inquire About Resident Privilege Onboarding